Asset
Carboplatin
Revenue
No revenue reported in loaded filings.
Clinical trials (3)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06915025 | phase3 | recruiting | 2025-07-09 | 2032-10-31 | Imunon | Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer |
| NCT05739981 | phase1_2 | recruiting | 2023-02-10 | 2027-06-30 | Imunon | Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer |
| NCT03393884 | phase1_2 | active_not_recruiting | 2018-09-05 | 2024-07-25 | Imunon | Study of IMNN-001 (Also Known as GEN-1) With NACT for Treatment of Ovarian Cancer (OVATION 2) |
FDA applications (0)
This company has no applications containing this asset.